Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan

IMPORTANCE: A surrogate end point (SEP) is an end point used in clinical trials as an alternative for measuring the true clinical benefit. The use of SEPs in trials shortens their duration. OBJECTIVES: To investigate the use of SEPs in clinical trials to support the approval of anticancer drugs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Hideki, Shingai, Riko, Takeda, Kentaro, Hara, Asuka, Murai, Yuna, Ofuchi, Momoka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148198/
https://www.ncbi.nlm.nih.gov/pubmed/37115550
http://dx.doi.org/10.1001/jamanetworkopen.2023.8875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148198/
https://www.ncbi.nlm.nih.gov/pubmed/37115550
http://dx.doi.org/10.1001/jamanetworkopen.2023.8875

Ejemplares similares